

CLOSURE OF ENTITLEMENT OFFER AND NOTIFICATION OF SHORTFALL

Perth, Australia, 10 July 2019: BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**), a medical technology company developing non-invasive cancer diagnostics, is pleased to announce that the non-renounceable Entitlement Offer (**Offer**) to raise approximately \$2.5 million (before costs) closed at 3:00pm (WST) on Friday, 5 July 2019 as per the terms of the Offer.

The Company has received applications to subscribe for 65,927,194 new shares in the Company from eligible shareholders under the Offer, raising \$1,318,543.88.

All new shares to be issued under the Entitlement Offer will, from their relevant issue date, rank equally in all respects with the existing fully paid ordinary shares of the Company.

As outlined in the Offer Document, the Company entered into a mandate letter (**Mandate**) with Merchant Corporate Advisory Pty Ltd who have agreed under the Mandate to subscribe for and/or place any unallocated shortfall shares under the Offer.

Additionally, the Company entered into Underwriting Agreements with companies controlled by non-executive directors Max Johnston and Philip Powell to partially underwrite the Offer as detailed in the Offer Document (being aggregate underwriting of 10,000,000 new shares in the Company at \$0.02 per share). No underwriting fees are payable under the terms of the Underwriting Agreements.

Please refer to the Offer Document for further information, including the indicative timetable.

- ENDS -

COMPANY CONTACTS:

Dr Leearne Hinch
CEO
E leearne@bard1.com
M +61 400 414 416

Peter Gunzburg
Chairman
E peter@bard1.com

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian medical technology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1 owns a proprietary tumour marker platform with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes BARD1 autoantibody tests in development for early detection of breast, ovarian and lung cancers. BARD1's mission is to detect cancer earlier and save lives. For more information on BARD1, see www.bard1.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.

IMPORTANT NOTICES

This notice is issued by the Company. This notice is not a prospectus or offering document under Australian law or under any other law. It is for information purposes only and does not constitute an offer, invitation or recommendation to subscribe for, retain or purchase any securities in the Company in any jurisdiction. This announcement does not constitute financial product advice and does not and will not form part of any contract for the acquisition of ordinary shares in the Company.

The provision of this document is not, and should not be considered as, a securities recommendation or financial product advice. The information in this document is general information only, and does not take into account your individual objectives, taxation position, financial situation or needs. Before acting on the information, you should consider the appropriateness of the information, having regard to your objectives, taxation position, financial situation or needs. If you are unsure of your position, please contact your stockbroker, accountant, taxation adviser, financial adviser or other professional adviser.

HONG KONG

WARNING: The contents of this document have not been reviewed by any Hong Kong regulatory authority. You are advised to exercise caution in relation to this document. If you are in doubt about any contents of this document, you should obtain independent professional advice.

SWITZERLAND

The New Shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange ("SIX") or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any offering or marketing material relating to the New Shares may be publicly distributed or otherwise made publicly available in Switzerland.

Neither this document nor any offering or marketing material relating to the New Shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of New Shares will not be supervised by, the Swiss Financial Market Supervisory Authority (FINMA). This document is personal to the recipient only and not for general circulation in Switzerland.

UNITED STATES

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this document have not been, and will not be registered, under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the US Securities Act of 1933 and applicable US state securities laws.